Company Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing, licensing, and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablet for the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS); Fycompa is used to treat certain types of focal onset seizures; and Ruzurgi is for the treatment of pediatric LEMS patients.
The company develops Firdapse for the treatment of MuSK antibody-positive myasthenia gravis and spinal muscular atrophy type.
It has license agreements with BioMarin Pharmaceutical Inc. for the North American rights to Firdapse; an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. for the rights to develop and commercialize Ruzurgi; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was founded in 2002 and is based in Coral Gables, Florida.
| Country | United States |
| Founded | 2002 |
| IPO Date | Nov 8, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Richard John Daly |
Contact Details
Address: 355 Alhambra Circle, Suite 801 Coral Gables, Florida 33134 United States | |
| Phone | 305 420 3200 |
| Website | catalystpharma.com |
Stock Details
| Ticker Symbol | CPRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001369568 |
| CUSIP Number | 14888U101 |
| ISIN Number | US14888U1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard John Daly M.B.A. | President, Chief Executive Officer and Director |
| Dr. Steven R. Miller Ph.D. | Executive Vice President, Chief Operating Officer and Chief Scientific Officer |
| Dr. Gary Ingenito M.D., Ph.D. | Chief Medical and Regulatory Officer |
| Jeffrey Del Carmen | Executive Vice President and Chief Commercial Officer |
| Michael W. Kalb CPA | Executive Vice President, Treasurer and Chief Financial Officer |
| Mary Coleman | Vice President and Head of Investor Relations |
| Brian Elsbernd J.D. | Chief Compliance Officer and Chief Legal Officer |
| Dr. Stanley Iyadurai M.D., Ph.D. | Senior Vice President of Medical Affairs and Drug Discovery |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer |
| Philip B. Schwartz Esq. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |